Safety and efficacy of drug-eluting beads versus conventional bronchial arterial chemoembolization for lung cancer: a systematic review and meta-analysis - Scorecard - MDSpire
Advertisement
Comparative Analysis of Drug-Eluting Beads and Standard Bronchial Arterial Chemoembolization for Lung Cancer: A Systematic Review and Meta-Analysis
Clinical Scorecard: Comparative Analysis of Drug-Eluting Beads and Standard Bronchial Arterial Chemoembolization for Lung Cancer: A Systematic Review and Meta-Analysis
At a Glance
Category
Detail
Condition
Lung Cancer
Key Mechanisms
Bronchial arterial infusion chemotherapy with or without embolization using drug-eluting beads.
Target Population
Patients with unresectable lung cancer.
Care Setting
Oncologic treatment settings.
Key Highlights
DEB-BACE associated with higher pooled ORR and DCR at 1–3 months and 6 months compared to cBACE.
No significant differences in adverse events such as hemoptysis, fever, or nausea/vomiting between DEB-BACE and cBACE.
Evidence based on five studies involving 221 patients, primarily from China.
Guideline-Based Recommendations
Diagnosis
Evaluate lung cancer using imaging and histopathological confirmation.
Management
Consider DEB-BACE for patients with advanced lung cancer, particularly those with hemoptysis or chemotherapy-refractory disease.
Monitoring & Follow-up
Monitor tumor response using ORR and DCR as per RECIST criteria.
Risks
Assess for potential treatment-related adverse events, though they appear manageable in DEB-BACE.
Patient & Prescribing Data
Patients with unresectable lung cancer, particularly those with limited treatment options.
DEB-BACE may enhance therapeutic outcomes without significantly increasing adverse events.
Clinical Best Practices
Utilize a multidisciplinary approach for managing advanced lung cancer.
Ensure informed consent regarding the risks and benefits of DEB-BACE versus cBACE.
